ICL: Sales and adjusted EBITDA grew as portfolio resilience offset cost and market pressures
ICL Group reported Q3 sales up 3% YoY and adjusted EBITDA up 1%, with adjusted net income rising 2%. Segment results varied. The company reiterated its FY26 guidance, citing pricing and cost actions to offset market pressures.
How this was made

The 30-second read
Why it matters
The earnings release provides fresh data that could adjust short‑term pricing expectations for ICL.
Market read
First report of Q3 results; modest growth may lead to limited price movement.
What to watch
Potential impact of raw‑material and freight cost volatility on future earnings.
Background
ICL Group Ltd. released its Q3 2026 earnings via a SEC 6‑K filing, highlighting modest revenue and EBITDA growth.
Ticker impact
Q3 sales rose 3% YoY and adjusted EBITDA increased 1% as reported in ICL's SEC 6‑K filing.
potential modest move as market digests the modest growth and reaffirmed FY26 guidance
Numbers are new and directly from the filing; impact likely limited to short‑term price adjustment.
Market effects
Provides a modest positive signal for the specialty chemicals sector.
May slightly influence Israeli and broader European chemical markets.
Limited global impact; primarily relevant to investors in ICL and peers.
Counterpoint
Growth is modest and may not justify a price rally; cost pressures could weigh on margins.
Key entities
- CompanyICL Group Ltd.
Israeli chemicals producer listed on NYSE under ticker ICL.




